China Japan Usa covid-19 testing RNA patient China Japan Usa

Influenza drug Favipiravir being tested to treat COVID-19

Reading now: 119
www.pharmaceutical-technology.com

The influenza antiviral favipiravir was tested in clinical trials with COVID-19 patients in China and showed a shorter viral clearance time than the control group that received the anti-HIV combo lopinavir/ritonavir.

Credit: Antipina Daria via Shutterstock. Treatment options for COVID-19 are urgently needed as the total number of confirmed cases globally rises to 550,000 on Friday and the US becomes the country with the most confirmed cases, at over 86,000.

One of the potentially quickest ways to find treatment is to test substances already approved or in development for other indications.

The influenza antiviral favipiravir, marketed as Avigan by Fujifilm Toyama in Japan, was tested in clinical trials with COVID-19 patients in China and

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA